Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19434170 | 1.00 | GPR119 (0.55) | GPR119CYP2C9F2RL3KCNH2 | |
| SCHEMBL29966755 | 1.00 | GPR119 (0.55) | GPR119CYP2C9F2RL3KCNH2 | |
| SCHEMBL29966702 | 1.00 | GPR119 (0.55) | GPR119CYP2C9F2RL3KCNH2 | |
| SCHEMBL29966725 | 0.93 | GPR119 (0.47) | GPR119CYP2C9F2RL3 | |
| SCHEMBL19434218 | 0.93 | GPR119 (0.47) | GPR119CYP2C9F2RL3 | |
| SCHEMBL29966962 | 0.93 | GPR119 (0.47) | GPR119CYP2C9F2RL3 | |
| SCHEMBL19434302 | 0.93 | GPR119 (0.47) | GPR119CYP2C9F2RL3 | |
| SCHEMBL19438327 | 0.92 | GPR119 (0.45) | GPR119CYP2C9F2RL3 | |
| SCHEMBL19434260 | 0.92 | GPR119 (0.52) | GPR119CYP2C9F2RL3 | |
| SCHEMBL19434291 | 0.92 | GPR119 (0.52) | GPR119CYP2C9F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208030-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2019-02-19 | — | — | US | claimed |
| EP-3440078-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2019-02-13 | — | — | EP | claimed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | claimed |
| WO-2017175066-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | claimed |
| EP-3440078-B1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2022-09-28 | — | — | EP | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2019-05-02 | — | — | US | disclosed |
| US-10208030-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-10208030-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| EP-3440078-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2019-02-13 | — | — | EP | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| WO-2017175066-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175066-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | GPR119 1/4885CYP2C9 1058/4885F2RL3 582/4885 |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | GPR119 1/4885CYP2C9 1058/4885F2RL3 582/4885 |
| US-10752622-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | GPR119 1/4885CYP2C9 1274/4885F2RL3 678/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | GPR119 1/4885CYP2C9 1274/4885F2RL3 678/4885 |
| US-10208030-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | GPR119 1/4885CYP2C9 1274/4885F2RL3 678/4885 |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | GPR119 1/4885CYP2C9 1058/4885F2RL3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.